MNKD Mannkind Corp

Price (delayed)

$4.86

Market cap

$1.32B

P/E Ratio

121.5

Dividend/share

N/A

EPS

$0.04

Enterprise value

$1.64B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
Mannkind's EPS has soared by 200% from the previous quarter and by 114% YoY
Mannkind's net income has soared by 171% from the previous quarter and by 112% YoY
The company's debt rose by 33% YoY

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
272.32M
Market cap
$1.32B
Enterprise value
$1.64B
Valuations
Price to earnings (P/E)
121.5
Price to book (P/B)
N/A
Price to sales (P/S)
5.85
EV/EBIT
41.48
EV/EBITDA
35.91
EV/Sales
7.3
Earnings
Revenue
$224.6M
EBIT
$39.53M
EBITDA
$45.65M
Free cash flow
$3.1M
Per share
EPS
$0.04
Free cash flow per share
$0.01
Book value per share
-$0.85
Revenue per share
$0.83
TBVPS
$1.77
Balance sheet
Total assets
$480.88M
Total liabilities
$710.85M
Debt
$509.29M
Equity
-$229.97M
Working capital
$283.21M
Liquidity
Debt to equity
-2.21
Current ratio
3.84
Quick ratio
3.21
Net debt/EBITDA
6.92
Margins
EBITDA margin
20.3%
Gross margin
71%
Net margin
3.8%
Operating margin
13.8%
Efficiency
Return on assets
2.1%
Return on equity
N/A
Return on invested capital
6.7%
Return on capital employed
10.4%
Return on sales
17.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
1.67%
1 week
-3.57%
1 month
3.4%
1 year
20.9%
YTD
33.52%
QTD
7.28%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$224.6M
Gross profit
$159.44M
Operating income
$30.96M
Net income
$8.49M
Gross margin
71%
Net margin
3.8%
MNKD's operating income has soared by 192% QoQ and by 161% YoY
Mannkind's net income has soared by 171% from the previous quarter and by 112% YoY
The company's net margin has surged by 163% QoQ and by 107% YoY
MNKD's operating margin has surged by 160% since the previous quarter and by 135% year-on-year

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
121.5
P/B
N/A
P/S
5.85
EV/EBIT
41.48
EV/EBITDA
35.91
EV/Sales
7.3
Mannkind's EPS has soared by 200% from the previous quarter and by 114% YoY
The equity has increased by 10% year-on-year and by 7% since the previous quarter
The revenue has soared by 75% YoY and by 13% from the previous quarter
The P/S is 36% lower than the 5-year quarterly average of 9.2

Efficiency

How efficient is Mannkind business performance
The company's return on invested capital has surged by 179% YoY and by 148% QoQ
The ROA has soared by 162% QoQ and by 109% YoY
Mannkind's ROS has soared by 149% YoY and by 138% from the previous quarter

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 32% lower than its total liabilities
The company's total assets has surged by 61% YoY
The company's current ratio rose by 41% YoY and by 7% QoQ
The debt to equity is down by 47% year-on-year and by 6% since the previous quarter
The company's debt rose by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.